注意缺陷多动障碍药物疗效与耐受性的系统综述与网络Meta分析
该系统综述与网络Meta分析纳入133项双盲随机对照试验,比较多种口服药物在儿童青少年及成人ADHD中的疗效与耐受性。结果显示,儿童青少年中医师评定的所有药物均优于安慰剂,但教师评定仅哌甲酯和莫达非尼优于安慰剂;成人中安非他明、哌甲酯、安非他酮和托莫西汀优于安慰剂。耐受性方面,安非他明在儿童青少年和成人中均劣于安慰剂;胍法辛仅在儿童青少年中劣于安慰剂;托莫西汀、哌甲酯和莫达非尼仅在成人中劣于安慰剂。头对头比较中,安非他明疗效优于莫达非尼、托莫西汀和哌甲酯。综合疗效与安全性,支持儿童青少年首选哌甲酯、成人首选安非他明作为短期治疗药物。
要点
- 儿童青少年中医师评定所有药物优于安慰剂,教师评定仅哌甲酯和莫达非尼优于安慰剂。
- 成人中安非他明、哌甲酯、安非他酮和托莫西汀优于安慰剂,莫达非尼不优于安慰剂。
- 安非他明在儿童青少年和成人中耐受性均劣于安慰剂,胍法辛仅在儿童青少年中劣于安慰剂。
核心结论
- 综合疗效与安全性证据支持儿童青少年首选哌甲酯、成人首选安非他明作为ADHD短期治疗药物。
- 需紧急资助新研究评估这些药物的长期效应。
研究设计与样本
- 系统检索已发表和未发表的双盲随机对照试验,比较安非他明类(包括赖氨酸安非他明)、托莫西汀、安非他酮、可乐定、胍法辛、哌甲酯和莫达非尼之间或与安慰剂的疗效。
- 共纳入133项双盲随机对照试验(81项在儿童青少年,51项在成人,1项两者均有)。
- 主要结局为疗效(基于教师和临床医生评定的ADHD核心症状严重程度变化)和耐受性(因副作用脱落的比例),时间点最接近12周、26周和52周。
- 使用随机效应配对和网络Meta分析估计汇总比值比(OR)和标准化均数差(SMD),采用Cochrane偏倚风险工具评估个体研究偏倚风险,采用GRADE方法评估网络Meta分析证据置信度。
- 研究注册号PROSPERO CRD42014008976。
临床怎么用
- 儿童青少年ADHD短期治疗可优先考虑哌甲酯,成人可优先考虑安非他明,需结合疗效与耐受性个体化选择。
- 临床医生评定与教师评定结果存在差异,评估疗效时应综合多来源信息。
- 处方时需关注药物耐受性,安非他明在儿童青少年和成人中因副作用脱落风险均较高。
局限性
- 26周和52周时间点数据不足,无法评估长期疗效与耐受性。
- 多数间接比较的证据置信度为低或极低。
- 教师评定数据仅部分药物可用,限制了疗效比较的全面性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain controversial, and guidelines are inconsistent on which medications are preferred across different age groups. We aimed to estimate the comparative efficacy and tolerability of oral medications for ADHD in children, adolescents, and adults. METHODS: We did a literature search for published and unpublished double-blind randomised controlled trials comparing amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with each other or placebo. We systematically contacted study authors and drug manufacturers for additional information. Primary outcomes were efficacy (change in severity of ADHD core symptoms based on teachers' and clinicians' ratings) and tolerability (proportion of patients who dropped out of studies because of side-effects) at timepoints closest to 12 weeks, 26 weeks, and 52 weeks. We estimated summary odds ratios (ORs) and standardised mean differences (SMDs) using pairwise and network meta-analysis with random effects. We assessed the risk of bias of individual studies with the Cochrane risk of bias tool and confidence of estimates with the Grading of Recommendations Assessment, Development, and Evaluation approach for network meta-analyses. This study is registered with PROSPERO, number CRD42014008976. FINDINGS: 133 double-blind randomised controlled trials (81 in children and adolescents, 51 in adults, and one in both) were included. The analysis of efficacy closest to 12 weeks was based on 10 068 children and adolescents and 8131 adults; the analysis of tolerability was based on 11 018 children and adolescents and 5362 adults. The confidence of estimates varied from high or moderate (for some comparisons) to low or very low (for most indirect comparisons). For ADHD core symptoms rated by clinicians in children and adolescents closest to 12 weeks, all included drugs were superior to placebo (eg, SMD -1·02, 95% CI -1·19 to -0·85 for amphetamines, -0·78, -0·93 to -0·62 for methylphenidate, -0·56, -0·66 to -0·45 for atomoxetine). By contrast, for available comparisons based on teachers' ratings, only methylphenidate (SMD -0·82, 95% CI -1·16 to -0·48) and modafinil (-0·76, -1·15 to -0·37) were more efficacious than placebo. In adults (clinicians' ratings), amphetamines (SMD -0·79, 95% CI -0·99 to -0·58), methylphenidate (-0·49, -0·64 to -0·35), bupropion (-0·46, -0·85 to -0·07), and atomoxetine (-0·45, -0·58 to -0·32), but not modafinil (0·16, -0·28 to 0·59), were better than placebo. With respect to tolerability, amphetamines were inferior to placebo in both children and adolescents (odds ratio [OR] 2·30, 95% CI 1·36-3·89) and adults (3·26, 1·54-6·92); guanfacine was inferior to placebo in children and adolescents only (2·64, 1·20-5·81); and atomoxetine (2·33, 1·28-4·25), methylphenidate (2·39, 1·40-4·08), and modafinil (4·01, 1·42-11·33) were less well tolerated than placebo in adults only. In head-to-head comparisons, only differences in efficacy (clinicians' ratings) were found, favouring amphetamines over modafinil, atomoxetine, and methylphenidate in both children and adolescents (SMDs -0·46 to -0·24) and adults (-0·94 to -0·29). We did not find sufficient data for the 26-week and 52-week timepoints. INTERPRETATION: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs. FUNDING: Stichting Eunethydis (European Network for Hyperkinetic Disorders), and the UK National Institute for Health Research Oxford Health Biomedical Research Centre.
引用
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018. PMID: 30097390. doi:10.1016/S2215-0366(18)30269-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。